International Journal of Radiation Oncology * Biology * Physics
Volume 74, Issue 2 , Pages 383-387 , 1 June 2009

RTOG GU Radiation Oncology Specialists Reach Consensus on Pelvic Lymph Node Volumes for High-Risk Prostate Cancer

  • Colleen A.F. Lawton, M.D.

      Affiliations

    • Medical College of Wisconsin, Milwaukee WI
    • Corresponding Author InformationReprint requests to: Colleen A. F. Lawton, M.D., Radiation Oncology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee WI 53226. Tel: (414) 805-4472; Fax: (414) 805-4369
    • ,
  • Jeff Michalski, M.D.

      Affiliations

    • Washington University, St. Louis, MO
    • ,
  • Issam El-Naqa, Ph.D.

      Affiliations

    • Mallinckrodt Institute of Radiology, St. Louis, MO
    • ,
  • Mark K. Buyyounouski, M.D.

      Affiliations

    • Fox Chase Cancer Center, Philadelphia, PA
    • ,
  • W. Robert Lee, M.D.

      Affiliations

    • Wake Forest University School of Medicine, Winston-Salem, NC
    • ,
  • Cynthia Menard, M.D.

      Affiliations

    • PMH-UHN University of Toronto, Toronto, Ontario, Canada
    • ,
  • Elizabeth O'Meara, M.D.

      Affiliations

    • American College of Radiology, Philadelphia, PA
    • ,
  • Seth A. Rosenthal, M.D.

      Affiliations

    • Radiation Oncology Center, Radiological Associates of Sacramento, Sacramento, CA
    • ,
  • Mark Ritter, M.D.

      Affiliations

    • University of Wisconsin School of Medicine and Public Health, Madison, WI
    • ,
  • Michael Seider, M.D.

      Affiliations

    • Akron City Hospital, Akron, OH

Received 18 June 2008 ,Revised 30 July 2008 ,Accepted 2 August 2008.

References 

  1. Pilepich M, Winter K, Lawton C, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma long term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61(5):1285–1290
  2. Roach M, Bae K, Speight J, et al. Short term neoadjuvant androgen deprivation therapy and external beam radiotherapy for locally advanced prostate cancer: long term results of RTOG 8610 a Phase III prospective randomized trial. J Clin Oncol. 2008;26(4):585–591
  3. Horwitz E, Bae K, Hanks G, et al. Ten-year follow-up of RTOG 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26:2497–2504
  4. Bolla M, Collette L, Blank L, et al. Long term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study, a phase III randomized trial). Lancet. 2002;360:103–108
  5. Roach M, DeSilvio M, Valicenti R, et al. Whole-pelvis, “mini-pelvis,” or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys. 2006;66(3):647–653
  6. RTOG 05-21: A phase III protocol of androgen suppression (AS) and 3D CRT/IMRT vs AS and 3D CRT/IMRT followed by chemotherapy with docetaxel and prednisone for localized high risk prostate cancer. Available at: http://rtog.org. Accessed September 10, 2008.
  7. RTOG 05-34: A phase III trial of short term androgen deprivation with pelvic lymph node or prostate bed only radiotherapy (SPPORT) in prostate cancer patients with a rising PSA after radical prostatectomy. Available at: http://rtog.org. Accessed September 10, 2008.
  8. Lawton CA, Michalski J, El-Naqa I, et al. Variation in the definition of clinical target volumes for pelvic node conformal radiation therapy of prostate cancer. [abstract 2224] Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S327
  9. Raghavalah NV, Jordan WP. Prostatic lymphography. J Urol. 1979;121:178–181
  10. Cerny JC, Farah R, Rian R, et al. An evaluation of lymphangiography in staging carcinoma of the prostate. J Urol. 1975;113:367–370
  11. Golimbu M, Morales P, Al-Askari S, et al. Extended pelvic lymphadenectomy for prostate cancer. J Urol. 1979;121:617–620
  12. Bader P, Burkhard F, Markwalder R, et al. Is a limited node dissection an adequate staging procedure for prostate cancer?. J Urol. 2002;168:514–518
  13. Burkhard F, Schumacker M, Thalmann GN, et al. Is pelvic lymphadenectomy really necessary in patients with a serum prostate-specific antigen level of <10 ng/ml undergoing radical prostatectomy for prostate cancer?. BJU Int. 2005;95:275–280
  14. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol. 2002;167:1681–1686
  15. Allaf M, Palapattu G, Trock G, et al. Anatomical extent of lymph node dissection: Impact on men with clinically localized prostate cancer. J Urol. 2004;172:1840–1844
  16. Wawroschek F, Vogt H, Weckermann D, et al. The sentinel lymph node concept in prostate cancer: First results of gamma probe-guided sentinel lymph node identification. Eur Urol. 1999;36:595–600
  17. Takashima H, Egawa M, Imao T, et al. Validity of sentinel lymph node concept for patients with prostate cancer. J Urol. 2004;171:2268–2271
  18. Weckermann D, Dorn R, Trefz M, et al. Sentinel lymph node dissection for prostate cancer: Experience with more than 1,000 patients. J Urol. 2007;177:916–920
  19. Netter F. Atlas of human anatomy. 2nd ed. East Hanover, NJ: Novartis; 1997;p. 379
  20. Gil-Vernet JM. Prostate cancer: anatomical and surgical considerations. Br J Urol. 1996;78:161–168
  21. Shih H, Harisinghani M, Zietman A, et al. Mapping of nodal disease in locally advanced prostate cancer: Rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. J Int Radiat Oncol Biol Phys. 2005;63(4):1262–1269
  22. Taylor A, Rockall A, Reznek R, et al. Mapping pelvic lymph nodes: Guidelines for delineation in intensity modulated radiotherapy. J Int Radiat Oncol Biol Phys. 2005;63(5):1604–1612
  23. American Cancer Society . Cancer facts and figures 2007. Atlanta: American Cancer Society; 2007;
  24. Small W, Mell LK, Anderson P, et al. Consensus guidelines for the delineation of the clinical target volume for intensity modulated pelvic radiotherapy in the postoperative treatment of endometrial and cervical cancer. J Int Radiat Oncol Biol Phys. 2008;71(2):428–434

 Supported by grants from the National Cancer Institute, CA21661, CA32115, and CA37422.

 Conflict of interest: none

PII: S0360-3016(08)03266-5

doi: 10.1016/j.ijrobp.2008.08.002

International Journal of Radiation Oncology * Biology * Physics
Volume 74, Issue 2 , Pages 383-387 , 1 June 2009

Article Tools

* Image Usage & Resolution